Express Pharma
Home  »  Latest Updates  »  Lupin gets US FDA approval for Sulfamethoxazole and Trimethoprim

Lupin gets US FDA approval for Sulfamethoxazole and Trimethoprim

It is a generic equivalent of Sun Pharmaceutical Industries's bactrim oral suspension

0 203
Read Article

Lupin has received the United States Food and Drug Administration approval for its Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL.

The approval is to market a generic equivalent of bactrim oral suspension, 200 mg/40 mg per 5 mL, of Sun Pharmaceutical Industries.

Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, is indicated for the treatment and prevention of a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections), and certain type of pneumonia (pneumocystis-type).

According to the IQVIA MAT September 2020 data, Sulfamethoxazole and Trimethoprim Oral Suspension USP had estimated annual sales of approximately US $19 million in the US.

Leave A Reply

Your email address will not be published.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Attend India's Largest Pharma Packaging & Labelling Conclave
Register Now
close-image